#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Asthma Dermatitis atopic Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Chronic graft versus host disease in intestine Small for dates baby Subarachnoid haemorrhage Anti-neutrophil cytoplasmic antibody positive vasculitis Anal cancer Thromboangiitis obliterans Ovarian cancer stage III Endometrial adenocarcinoma Cerebellar ataxia Short stature Small intestine adenocarcinoma Malignant oligodendroglioma Brain injury Renal cell carcinoma Congenital disorder of glycosylation More trials…

    Learn about Rare Diseases

    Congenital nephrogenic diabetes insipidus – Trials in Disease Factor IX deficiency Ornithine transcarbamoylase deficiency Choroid melanoma – Treatment Mantle cell lymphoma stage IV – Basic Information Wolfram syndrome Ewing’s sarcoma metastatic – Basic Information Rhabdomyosarcoma recurrent Marfan’s syndrome – Basic Information Waldenstrom’s macroglobulinaemia refractory More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Danicamtiv Naloxegol Oxalate Rtp-026 Sodium Avibactam HYPOCHLOROUS ACID Almagate Ion440 Gelatin Tertomotide Rozanolixizumab Bi 3720931 Lactose Monohydrate Oms906 Bromocriptine Aavanc80-3'Hotof Tiotropium Bi 1291583 Baloxavir Marboxil Sacubitril Valsartan Ramipril More therapies…

    Learn about Your Condition

    Barrett's oesophagus Congenital myopathy PIK3CA-activated mutation Neuromyopathy Hyperplasia adrenal Pancreatitis acute Cortisol abnormal Fragile X syndrome Optic glioma Endometrial cancer stage I Atrial fibrillation Thalassaemia alpha Malignant melanoma stage IV Sarcoidosis Acute leukaemia More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Central nervous system melanoma

  • Study of Encorafenib, Binimetinib, and Pembrolizumab for Patients with Advanced Melanoma with BRAF V600E/K Mutation

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Binimetinib
    • Encorafenib
    • Pembrolizumab
    Belgium Bulgaria Czechia Finland Germany Greece +5

  • Study of Encorafenib, Binimetinib, and Pembrolizumab for Patients with BRAF V600E/K Mutation-Positive Melanoma After Anti-PD-1 Therapy

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Central nervous system melanoma
    • Gastrointestinal melanoma
    • Malignant melanoma of eyelid
    Investigated Drugs:
    • Binimetinib
    • Encorafenib
    • Ipilimumab
    Germany Italy Poland Slovakia Spain

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!